STAT+: AstraZeneca drug prevents breast cancer caused by BRCA mutations from returning
Lynparza, a cancer-fighting pill marketed by AstraZeneca and Merck, reduced the risk that breast cancer…
Category: Pharmaceuticals
STAT+: After repeated losses in the U.S., Catalyst wins a victory in Canada over a rare disease drug
In an unexpected move, Canada’s Federal Court quashed the approval of a rare disease drug…
.jpg)
STAT+: Former Celgene shareholders claim Bristol Myers reaped a $6.4 billion windfall by delaying a drug approval
A lymphoma drug that was approved later than expected by regulators is at the center…
STAT+: A bootcamp for digital health executives seeks to demystify the inner-workings of the drug industry
Naomi Fried has watched the same plot unfold over and over again: A digital health…
Opinion: If the FDA approves Biogen’s Alzheimer’s treatment, I won’t prescribe it
Most visits to the memory center where I care for individuals living with Alzheimer’s disease…
Opinion: STAT+: SARS-CoV-2 brought the world to its knees. Its digital twin is helping bring us back
“Bad news wrapped up in protein.” That’s how the late Nobel Laureate Sir Peter Medawar…
STAT+: FDA revives a controversial program the Trump administration ended over ‘inaccuracies’
In an unexpected move, the Food and Drug Administration is reversing a decision by the…
STAT+: Drug makers argue an HHS rule would penalize them for offering co-pay coupons
After months of controversy, the pharmaceutical industry’s biggest trade group has filed a lawsuit accusing…
‘There’s so much uncertainty’: As Mallinckrodt sells rare disease drug, parents worry about access
As it looks to emerge from bankruptcy, Mallinckrodt (MNK) has sold an experimental medicine that…
Opinion: Restore a better balance to public-private funding of biomedical research
The pharmaceutical industry says that if the U.S. reduces the astronomical drug prices paid by…
STAT+: Emergent was aware of vaccine manufacturing issues even as it collected $27 million a month from U.S.
Under a contract awarded by the Trump administration, Emergent BioSolutions (EBS) was paid $27 million…
STAT+: Your money or else: Some drug makers could be ‘highly’ susceptible to ransomware attacks
The latest high-profile incident of a ransomware attack caused one of the biggest gas and…
STAT+: Democrats call on FTC to investigate AbbVie’s Humira pricing strategy
WASHINGTON — Three powerful Democrats wrote to the Federal Trade Commission Tuesday urging them to…
STAT+: Congress is ready to grill AbbVie’s CEO over drug pricing
WASHINGTON — AbbVie CEO Richard Gonzalez is in for a congressional tongue-lashing of outsized proportion….
STAT+: Feds tell drug makers to offer discounts to safety-net hospitals or face penalties
After a year of controversy, the Health Resources and Services Administration notified six large drug…
Opinion: Nix the bald cancer patient motif. Precision medicine needs precision marketing
Every time I see a pharmaceutical or health care ad or other marketing material that…
Opinion: Make drug companies partners — not adversaries — to expand global Covid-19 vaccine access
The Biden administration’s announcement that it would support waiving patent protections for Covid-19 vaccines to…
STAT+: Brazil’s Supreme Court rules that patent extension rules are unconstitutional
The Brazilian Supreme Court ruled that a provision in the country’s intellectual property law allowing…
STAT+: A clinical trial coordinator is indicted for falsifying data in a Glaxo asthma drug study
A former study coordinator at a company hired to run a clinical trial of a…
.jpg)
STAT+: ‘More Amazon and less pharmacy’: one exec on the company’s strategy for prescription drugs
Amazon’s objectives for its nascent pharmacy business are straightforward: “better selection, better convenience, and better…
STAT+: Sanofi is accused of ‘widespread destruction’ of company e-mails tied to Zantac recalls
As litigation proceeds over the Zantac heartburn pill and a possible carcinogen, a court filing…
How digital pharmacies can expand access to specialized care
Even the most aggressive proponents of telehealth must concede that while technology can open the…
STAT+: WHO, international regulatory group urge pharma to publish clinical study reports
In a significant step toward greater transparency, the World Health Organization and the International Coalition…
Opinion: Rather than turning its back on the QALY, pharma should collaborate on efforts to improve it
A key element in the long-simmering debate on reining in drug prices in the United…
STAT+: Massachusetts sues Publicis for designing ‘marketing schemes’ to boost OxyContin sales
The Massachusetts attorney general has filed a lawsuit against Publicis Health, one of the world’s…
STAT+: The U.S. opened pandora’s box on IP waivers for Covid-19 vaccines. What happens now?
In a surprising move, the Biden administration has said it will support a controversial proposal…
STAT+: In Belgium, too many clinical trial sponsors waffle about reporting required results
The results of more than one-fifth of clinical trials that were conducted in Belgium have…
STAT+: Pharmalittle: Biden supports WTO proposal on Covid-19 vaccine IP; Biogen Alzheimer’s drug is cost-effective at $2,500
Good morning, everyone, how are you today? We are doing just fine, thank you, as…
Opinion: STAT+: Faster approval of complex generics is central to affordable, equitable care
The push to improve Americans’ use of effective and less-expensive generic medications is getting a…
STAT+: Rising wholesale drug prices really do matter to half of all commercially insured Americans
Although the pharmaceutical industry argues that wholesale prices do not accurately reflect prescription drug costs,…
Do public health officials need to be political activists? A fight over an HIV crisis renews the question
Most local health officials don’t accept their jobs expecting to be roped into political activism….
STAT+: Did someone say patent thicket? AbbVie CEO to testify before Congress about drug pricing tactics
As part of its probe into pharmaceutical industry pricing tactics, a Congressional committee next month…
STAT+: Global spending on medicines could hit $1.6 trillion by 2025 — and that doesn’t include Covid-19 vaccines
Global spending on medicines is forecast to grow between 3% and 6% annually and reach…
STAT+: Americans paid two to four times as much for some drugs as in three other countries
Amid national angst over the cost of prescription drugs, a new analysis finds that U.S….
STAT+: For the first time, the FDA may fine a drug maker for failing to post clinical trial results
The Food and Drug Administration is threatening to fine Acceleron Pharma (XLRN) for failing to…
Opinion: STAT+: More pharma companies should make the move toward B Corps sustainability
The gradual global shift towards sustainability, with an increased focus on climate change and environmental…
STAT+: Thanks to its Covid-19 response, pharma’s reputation among patient groups is climbing
Thanks to the rapid development of Covid-19 vaccines, nearly two-thirds of patient advocacy groups believe…
STAT+: U.K. lawmakers want Boris Johnson to disclose emails with pharma about a WTO proposal on Covid-19 vaccines
Two dozen U.K. lawmakers called on the government to publish all communications with drug makers…
STAT+: Down and out Down Under? Bristol Myers fights an ‘unreasonable’ Australian law over patents
Two big drug makers are challenging a provision in Australian patent law that they argue…
Opinion: To create value, pharma companies should prioritize innovation, not shareholders
Biogen announced its quarterly earnings on April 22 and revealed it had repurchased $600 million…
STAT+: New data point to benefits of Bristol’s novel psoriasis pill, but safety issues will be scrutinized
Last November and then again in February, Bristol Myers Squibb said its oral drug designed…
Opinion: Congress: stand up to the paper lobby and abolish outdated paper labeling for clinicians
There’s no place in health care for practices that fail to serve the best interests…
STAT+: Pfizer shareholders are urged to reject political spending that contradicts ‘company values’
Arguing that Pfizer’s political spending conflicts with the company’s publicly stated values, a philanthropic organization…
STAT+: Biden officials met privately with 3M, AmerisourceBergen, PhRMA and more to debate shoring up the national stockpile
WASHINGTON — The Biden administration met privately this month with some of the nation’s biggest…
STAT+: Advocacy groups outraged after PBM offers a $500 gift card to persuade patients to switch drugs
Dozens of patient advocacy groups are angry over an unusual move by a pharmacy benefits…
Opinion: STAT+: The FDA should embrace remote and automated drug inspection technology
While pharmaceutical regulatory authorities in other countries are employing creative ways like video-based remote inspections…
Opinion: STAT+: Developers of microbiome-based drugs face challenges. There are ways to overcome them
Manipulating the human microbiome appears to be an effective approach for treating a range of…
STAT+: A drug maker sues a medical journal, its editor, and several authors for libel
In an unusual move, Pacira Biosciences (PCRX) has filed a libel lawsuit against a medical…
Opinion: It’s time to get health care value assessment right
Trying to gauge the value of new drugs and devices is becoming increasingly important in…
First-of-its-kind study pits psilocybin against a common antidepressant
Can psilocybin, the active ingredient in psychedelic mushrooms, match the depression-combatting capabilities of a commonly…